Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28817910 | 0.82 | ALDH1A1 (0.49) | ALDH1A1KDM4EATMTRIM24TRIM33 | |
| SCHEMBL29728434 | 0.79 | ATM (0.55) | ALDH1A1KDM4EATMTRIM24TRIM33 | |
| SCHEMBL951470 | 0.79 | ATM (0.55) | ALDH1A1KDM4EATMTRIM24TRIM33 | |
| SCHEMBL951077 | 0.77 | GAA (0.50) | ALDH1A1KDM4EATMTRIM24TRIM33 | |
| SCHEMBL29728418 | 0.75 | ALDH1A1 (0.46) | ALDH1A1KDM4EATMTRIM24TRIM33 | |
| SCHEMBL28802572 | 0.75 | ALDH1A1 (0.46) | ALDH1A1KDM4EATMTRIM24TRIM33 | |
| SCHEMBL951211 | 0.75 | ALDH1A1 (0.54) | ALDH1A1KDM4EATMTRIM24TRIM33 | |
| SCHEMBL950454 | 0.75 | ALDH1A1 (0.46) | ALDH1A1KDM4EATMTRIM24TRIM33 | |
| SCHEMBL28802548 | 0.74 | ATM (0.69) | ALDH1A1KDM4EATMTRIM24TRIM33 | |
| SCHEMBL18071907 | 0.74 | ALDH1A1 (0.53) | ALDH1A1KDM4EATMTRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773314-A | Biarylaminoguanidine derivative | 上海拓界生物医药科技有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9815849-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-1937664-B1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL CO (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-20110071291-A1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | IKEGAMI HIROSHI | 2011-03-24 | — | — | US | disclosed |
| US-7867949-B2 | Hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-11 | — | — | US | disclosed |
| EP-2251336-A1 | Hydrazide compounds as intermediates of pesticides | Sumitomo Chemical Company, Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
| EP-2251336-A1 | Hydrazide compounds as intermediates of pesticides | Sumitomo Chemical Company, Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20090181956-A1 | Hydrazide Compound and Pesticidal Use of the Same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| CN-101287721-A | Hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL CO (JP) | 2008-10-15 | — | — | CN | disclosed |
| WO-2007043677-A9 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL CO (JP) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007043677-A9 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL CO (JP) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007043677-A1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | ALDH1A1 2424/4885KDM4E 1552/4885ATM 444/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | ALDH1A1 3670/4885KDM4E 317/4885ATM 2001/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | ALDH1A1 1723/4885KDM4E 1909/4885ATM 887/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | ALDH1A1 2424/4885KDM4E 1552/4885ATM 444/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | ALDH1A1 1723/4885KDM4E 1909/4885ATM 887/4885 |
| US-20110071291-A1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | ACHE, H1-2, H1-0 | ALDH1A1 238/4885KDM4E 1084/4885ATM 4153/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | ALDH1A1 3670/4885KDM4E 317/4885ATM 2001/4885 |
| US-20090181956-A1 | Hydrazide Compound and Pesticidal Use of the Same | ACHE, DDT, CAT | ALDH1A1 436/4885KDM4E 2028/4885ATM 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.